Established biomarkers of neurodegenerative diseases are tau protein measured in the cerebrospinal fluid (CSF), brain atrophy assessed by MRI and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) PET assessment of brain hypometabolism (Jack et al., 2013). This evidence concerns the gene MAPT and neurodegenerative disease.